KRAS and neoplasm: Early molecular studies attempted to elucidate tumour development from premalignant lesions to carcinoma by their genetic similarities [2, 3] using various technologies including cytogenetic analysis, Loss of Heterozygosity (LOH) studies, and mutations in known oncogenes/tumour suppressor genes (KRAS or TP53).